0000950170-23-024600.txt : 20230526 0000950170-23-024600.hdr.sgml : 20230526 20230526191049 ACCESSION NUMBER: 0000950170-23-024600 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230524 FILED AS OF DATE: 20230526 DATE AS OF CHANGE: 20230526 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MORTIMER IAN CENTRAL INDEX KEY: 0001619961 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36687 FILM NUMBER: 23971019 MAIL ADDRESS: STREET 1: C/O XENON PHARMACEUTICALS INC. STREET 2: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G4W8 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Xenon Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001582313 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 980661854 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G 48W BUSINESS PHONE: (604) 484-3300 MAIL ADDRESS: STREET 1: 200 - 3650 GILMORE WAY CITY: BURNABY STATE: A1 ZIP: V5G 48W 4 1 ownership.xml 4 X0407 4 2023-05-24 0001582313 Xenon Pharmaceuticals Inc. XENE 0001619961 MORTIMER IAN 200 - 3650 GILMORE WAY BURNABY Z4 V5G 4W8 CANADA (FEDERAL LEVEL) true true false false PRESIDENT & CEO false Common Shares 2023-05-24 4 M false 42592 9.44 A 48592 D Common Shares 2023-05-24 4 F false 7310 41.84 D 41282 D Common Shares 2023-05-24 4 S false 17069 41.44 D 24213 D Common Shares 2023-05-24 4 M false 20576 9.85 A 44789 D Common Shares 2023-05-24 4 F false 3902 41.84 D 40887 D Common Shares 2023-05-24 4 S false 13179 41.37 D 27708 D Common Shares 2023-05-24 4 M false 6172 9.85 A 33880 D Common Shares 2023-05-24 4 F false 1171 41.84 D 32709 D Common Shares 2023-05-24 4 S false 1407 41.49 D 31302 D Common Shares 14300 I By Spouse. Stock Option (Right to Buy) 9.44 2023-05-24 4 M false 42592 0 D 2023-07-31 Common Shares 42592 0 D Stock Option (Right to Buy) 9.85 2023-05-24 4 M false 20576 0 D 2024-01-13 Common Shares 20576 0 D Stock Option (Right to Buy) 9.85 2023-05-24 4 M false 6172 0 D 2024-01-13 Common Shares 6172 0 D The exercise price was converted from $9.76 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Represents the closing price of the Company's common shares on May 23, 2023 for purposes of net settlement calculations. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.29 to $41.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the Reverse Stock Split. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.26 to $41.47, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.48 to $41.52, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. The shares subject to the option are fully vested and exercisable. /s/ Cassandra Robinson, Attorney-in-fact 2023-05-26